Elypta interim study LEVANTIS-0087A results show glycosaminoglycan's potential to predict the risk of developing any cancer with a simple urine test
The results will be presented at the 2024 American Association for Cancer Research Annual Meeting
Stockholm, April 8, 2024: Swedish early cancer detection company Elypta announces that the interim results from the LEVANTIS-0087A study will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego during the Biomarker-Based Screening session on April 9 (1:30 - 5:00 PM PT).
The population-based case-control study included 2,054 adults over the age of 18 with no symptoms of cancer from the Lifelines Cohort Study in the Netherlands. The results indicate that urine profiles (or GAGomes) could identify people at higher risk of developing any type of cancer up to six years before diagnosis. Aberrant urine GAGomes correctly predicted 80% more adults who would develop cancer compared to a strategy using risk factors such as age and sex, which is the current approach used in cancer screening programs.
“Early detection of cancers through screening can reduce mortality. However, screening excludes individuals not considered at be at an increased risk of developing cancer as determined by age, sex, or tobacco use. No molecular biomarker is routinely used to predict risk,” says Francesco Gatto, the study’s Principal Investigator, Founder and CSO at Elypta. “Therefore, implementing urine GAGomes to risk-stratify screening could identify adults with an increased risk of developing cancer who are currently excluded from screening based on their age and/or sex. Considering that urine GAGomes can be sampled at home, this could also reduce inequalities in cancer screening.”
All participants who self-reported any type of cancer or died by the 2-year or 6-year study visit were confirmed in the Dutch Cancer Registry (cases) and matched 1:1 to randomly selected individuals (controls) for the interim analysis. Urine GAGomes were measured at the baseline visit and were found to be independent of risk factors such as age or sex.
In 2022, Elypta launched LEVANTIS-0087A to validate the clinical performance of glycosaminoglycans as metabolic biomarkers for Multi-Cancer Early Detection (MCED). The study aims to detect any type of cancer in close to 10,000 adults who show no symptoms or have any recent history of cancer.
For further information
About the poster presentation
Session: PO.PR01.06 - Biomarker-Based Screening
Poster: Section 31, Abstract 6088, Board #14
Presentation on April 9, 2024 at 1:30 – 5:00 PM
Title: Predicting the risk of any-type cancer in asymptomatic adults using noninvasive glycosaminoglycan profiling
Online: https://www.abstractsonline.com/pp8/#!/20272/presentation/5445
About Elypta’s Multi-Cancer Early Detection study LEVANTIS-0087A
LEVANTIS-0087A (LEV87A) is a retrospective in vitro diagnostics clinical validation population cohort-based case-control study to validate the diagnostic performance of free GAGome-based tests for multi-cancer early detection in adults asymptomatic for cancer with no recent history of cancer.
LEVANTIS-0087A is registered at ClinicalTrials.gov (NCT05235009).
About Elypta
Elypta is a Swedish cancer detection company focused on reducing cancer mortality by enabling earlier detection and closer monitoring. The metabolism-based liquid biopsy platform measures a novel panel of glycosaminoglycan biomarkers (GAGome) and algorithms trained to detect cancer-specific signatures. Elypta is advancing a broad study program across different cancers with the leading indications being early detection of recurrence in renal cell
carcinoma and multi-cancer early detection. www.elypta.com.
